Abstract #995915: Active Versus Inactive Thyroid Eye Disease: Symptom and Quality of Life Comparison in US Patients

Purpose. To evaluate the changes in the quality of life of patients with thyroid eye disease after different methods of orbital decompression. Materials and methods. The study included 24 patients (37 orbits) with thyroid eye disease, aged 41.6 20.6 (from 20 to 79 years), 18 women and 6 men. The patients were divided into two groups. The first group included 12 patients (19 orbits) who underwent orbital fat decompression. The second group included 12 patients (18 orbits) who underwent endoscopic endonasal bony orbital decompression. The Graves ophthalmopathy quality of life questionnaire (GO-QOL) was completed before surgery, and 3 and 6 months after it. Outcome analysis included also the assessment of visual acuity, proptosis, eyelid retraction, and palpebral fissure height. Results. The GO-QOL visual function scores in both groups did not change significantly in 3 and in 6 months after orbital decompression (p 0.05): in the first group, before and after 6 months, scores were 69.27 20.02 and 68.96 18.44, in the second group 53.13 29.13 and 57.81 23.56, respectively. An improvement in the GO-QOL visual function estimation was observed in those patients whose visual acuity improved after surgery. The GO-QOL facial appearance scores significantly improved 3 months after surgery, and continued to increase up to 6 months: in the first group, facial appearance scores improved from 23.96 23.01 to 48.42 25.56 (p = 0.004), in the second group from 47.92 21.04 to 66.15 23.15 (p = 0.037). Conclusions. Orbital decompression significantly improves the quality of life of patients with thyroid eye disease, this is primarily associated with an improvement in facial appearance.

Download Full-text

Quality of life in thyroid eye disease: impact of quality of care

Acta Endocrinologica ◽

10.1530/eje-11-0055 ◽

2011 ◽

Vol 164 (5) ◽

pp. 649-655 ◽

Cited By ~ 34

Author(s):

Stephanie Estcourt ◽

Anthony G Quinn ◽

Bijay Vaidya

Keyword(s):

Quality Of Life ◽

Quality Of Care ◽

Thyroid Eye Disease ◽

Eye Disease ◽

Facial Disfigurement ◽

Physical Discomfort ◽

Disease Impact ◽

Physical Consequences ◽

The Impact

Thyroid eye disease (TED) is a chronic debilitating condition causing physical discomfort, facial disfigurement and impaired visual function. The physical consequences of TED could have a negative and lasting impact on patients' employment, hobbies and psychosocial function. In this review, we assess the evidence of the impact of TED on patients' quality of life (QOL) and also explore the effects of suboptimal quality of care on QOL of patients with this disease. It is hoped that recent initiatives, including the Amsterdam declaration, to raise the quality of care for patients with TED will help to improve their QOL.

Download Full-text

Gender differences in clinical presentation and prognosis of thyroid eye disease

European Journal of Ophthalmology ◽

10.1177/1120672120964112 ◽

2020 ◽

pp. 112067212096411

Author(s):

Ofira Zloto ◽

Oded Sagiv ◽

Ayelet Priel ◽

Tali Cukierman-Yaffe ◽

Amir Tirosh ◽

...

Keyword(s):

Quality Of Life ◽

Thyroid Eye Disease ◽

Eye Disease ◽

Clinical Activity ◽

Life Questionnaire ◽

Men And Women ◽

Graves Orbitopathy ◽

Eye Examination ◽

Active Disease

Objective: To examine the clinical differences in manifestation, treatment, and prognosis of thyroid-eye-disease (TED) between men and women. Methods: This is a longitudinal cohort study. Men and women, who diagnosed with TED and treated at a multidisciplinary TED clinic, were compared regarding differences in demographics, eye examination, disease activity, and quality of life evaluation. Results: TED was diagnosed in 132 patients during the study period, and they included 38 men (28.78%) and 94 women (71.21%). There were six men and 20 women with active disease (Clinical-Activity-Score (CAS) ⩾ 3) during the entire follow-up period ( p < 0.01). The mean time from TED diagnosis to CAS ⩾ 3 was 4.50 years for men and 2.35 years for women ( p = 0.05). There were no significant differences in mean total Graves’ Orbitopathy-Quality-of-Life questionnaire (GO-QOL) score. However, mean GO-QOL subtotal score of external appearance of women was significantly lower compare to men in the first and last visit ( p = 0.04, 0.03, respectively). Conclusion: Active disease was more common in women and the time-from-diagnosis of TED to CAS ⩾ 3 was shorter among women. Moreover, the appearance QOL score of women was poorer. These findings should be taken into consideration when planning the timing of treatment and when choosing the best treatment for TED patients.

Download Full-text

Evaluation of thyroid eye disease: quality-of-life questionnaire (TED-QOL) in Korean patients

Canadian Journal of Ophthalmology ◽

10.1016/j.jcjo.2013.12.007 ◽

2014 ◽

Vol 49 (2) ◽

pp. 167-173 ◽

Cited By ~ 11

Author(s):

Byeong Jae Son ◽

Sang Yeul Lee ◽

Jin Sook Yoon

Keyword(s):

Quality Of Life ◽

Thyroid Eye Disease ◽

Eye Disease ◽

Life Questionnaire ◽

Quality Of Life Questionnaire ◽

Korean Patients

Download Full-text

Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts

Acta Endocrinologica ◽

10.1530/eje.0.1440311 ◽

2001 ◽

pp. 311-318 ◽

Cited By ~ 31

Author(s):

GE Krassas ◽

AE Heufelder

Keyword(s):

Quality Of Life ◽

Immunosuppressive Agents ◽

Somatostatin Analogs ◽

Thyroid Eye Disease ◽

Eye Disease ◽

Muscle Dysfunction ◽

Orbital Radiotherapy ◽

Beneficial Effects ◽

Limited Experience

Thyroid eye disease (TED) is a debilitating disease impairing the quality of life of affected patients. Treatment is often not satisfactory. This review summarizes the existing literature and discusses the most widely used forms of treatment for TED such as glucocorticoids (GCs), and other immunosuppressive agents. GCs are the most commonly used treatment in patients with TED. Other immunosuppressive agents such as cyclosporin A, azathioprin, cyclophosphamide and ciamexone have been used, but the results are modest at best and indicate an unfavorable benefit-risk relationship. Limited experience indicates that methotrexate may be effective even in patients with refractory TED. Somatostatin analogs, octreotide and lanreotide, may provide a valuable, although costly, therapeutic alternative to GCs. Orbital radiotherapy has been used in the management of TED for almost 60 years. However, its beneficial effects have been questioned recently by several studies, the details of which have not yet been published. Other studies have argued in favor of orbital radiotherapy; however, the benefits appear to be limited to improvement of extraocular muscle dysfunction.

Download Full-text